2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1589

Obesity and Vascular Factors May Play a Role In Persistent Depression Among Individuals With Systemic Lupus Erythematosus
Abstract Number: 2817

Objective Assessment Of Musculoskeletal Physical Examination Skills During Continuing Education Programs For Primary Care Providers Adds Significant Information Not Obtained Through Self-Assessment
Abstract Number: 1979

Occupational Balance Questionnaire: From People’s Perspectives To A Patient Reported Outcome
Abstract Number: 1611

Off-Label Use Of Rituximab For Systemic Lupus Erythematosus in Europe: Limited Use Mostly In Refractory Patients
Abstract Number: 1822

Oleanolic Acid Acetate Inhibits Osteoclast Differentiation By Downregulating Phospholipase Cγ² –calcium ion oscillation-Nuclear Factor Of Activated T Cell c1 Signaling, and Suppresses Bone Loss In Mice
Abstract Number: 83

Oleuropein Or Rutin Consumption Decreases The Spontaneous Development Of OA In Hartley Guinea Pig
Abstract Number: 2660

Omega-3 Supplement Use Is Associated With a Reduced Risk Of Anti-Cyclic Citrullinated Protein Positivity In a Population Without Rheumatoid Arthritis, But At Risk For Future Disease
Abstract Number: 226

Omeract Definitions For The Sonographic Appearance Of The Normal Pediatric Joint
Abstract Number: 2850

Once Daily Controlled-Release Pregabalin In Fibromyalgia Patients: A Phase 3 Double-Blind, Randomized Withdrawal, Placebo-Controlled Study
Abstract Number: 1006

One-Year Change Of Employment and Work Productivity In Patients With Systemic Lupus Erythematosus From The Southeastern United States
Abstract Number: 2518

Only BAFF mRNA, Not BAFF Protein Level In Blood, Is Associated With SLE Activity Over One Year
Abstract Number: 16

Only IgG and IgA β₂glycoprotein I Antibody Isotypes Are Associated With Venous Thrombosis In Systemic Lupus Erythematosus
Abstract Number: 2291

Only Rheumatoid Factor-Positive Subset Of Anti-Citrullinated Peptide/Protein Antibody-Negative Rheumatoid Arthritis Seroconverts To Anti-Citrullinated Peptide/Protein Antibody-Positive
Abstract Number: 1824

ONO-4059 – A Novel Small Molecule Dual Inhibitor Of Bruton’s Tyrosine Kinase (Btk) and Tec Kinase- Suppresses Osteoclastic Bone Resorption and Inflammation
Abstract Number: 1110

Onychopathy: When Ultrasound Can Help The Dermatologist

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].